Due to the oncogenic function of CDK5, Dinaciclib, an effective inhibitor of CDK5, exerted potent tumor-suppressing effect in relapsed multiple myeloma and hepatocellular carcinoma [35, 36]. The gene discussed is CDK5; the disease is hepatocellular carcinoma.